(Q34268081)

1 August 2017

1 reference

title

The role of ABC transporters in clinical practice (English)

1 reference

1 August 2017

The Role of ABC Transporters in Clinical Practice (English)

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

antineoplastic resistance

18 March 2024

main subject

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14530494

18 March 2024

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

18 March 2024

3

Susan E Bates

1 reference

1 August 2017

2

Tito Fojo

1 reference

1 August 2017

Gregory D. Leonard

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14530494

18 March 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14530494

18 March 2024

publication date

1 January 2003

1 reference

full work available at URL

1 August 2017

http://theoncologist.alphamedpress.org/content/8/5/411.full.pdf

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14530494

https://onlinelibrary.wiley.com/doi/pdf/10.1634/theoncologist.8-5-411

18 March 2024

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

https://onlinelibrary.wiley.com/doi/full-xml/10.1634/theoncologist.8-5-411

18 March 2024

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

https://academic.oup.com/oncolo/article-pdf/8/5/411/41840007/oncolo_8_5_411.pdf

18 March 2024

file format

Portable Document Format

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

18 March 2024

1 reference

1 August 2017

volume

8

1 reference

1 August 2017

issue

5

1 reference

1 August 2017

page(s)

411-424

1 reference

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

1 August 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results

18 March 2024

2

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

18 March 2024

Multiple drug resistance

3

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

Resistance to targeted therapy in leukaemia

18 March 2024

4

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

Determinants of response and resistance to cytotoxics

18 March 2024

5

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

Apoptosis: implications of basic research for clinical oncology

18 March 2024

7

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

Antitopoisomerase drug action and resistance

18 March 2024

8

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

The induction of resistance to 4-amino-N10-methylpteroylglutamic acid in a strain of transmitted mouse leukemia.

18 March 2024

10

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells

18 March 2024

11

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants

18 March 2024

12

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

The mechanism of action of multidrug-resistance-linked P-glycoprotein

18 March 2024

15

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

Inhibitors of multidrug resistance to antitumor agents (MDR).

18 March 2024

16

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line

18 March 2024

17

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

A family of drug transporters: the multidrug resistance-associated proteins.

18 March 2024

18

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

Characterization of vincristine transport by the M(r) 190,000 multidrug resistance protein (MRP): evidence for cotransport with reduced glutathione

18 March 2024

19

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs

18 March 2024

22

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

MRP subfamily transporters and resistance to anticancer agents

18 March 2024

23

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells

18 March 2024

25

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

The role of HER-2 expression in predicting response to therapy in breast cancer

18 March 2024

29

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

Detection of in vivo P-glycoprotein inhibition by PSC 833 using Tc-99m sestamibi

18 March 2024

30

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

Expression of a multidrug-resistance gene in human tumors and tissues

18 March 2024

31

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

Expression of functional markers in acute nonlymphoblastic leukemia.

18 March 2024

32

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study

18 March 2024

33

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

P-glycoprotein in primary acute myeloid leukemia and treatment outcome of idarubicin/cytosine arabinoside-based induction therapy.

18 March 2024

34

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

Multidrug resistance-associated protein (MRP) in haematological malignancies

18 March 2024

35

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

Multidrug resistance mechanisms in chronic lymphocytic leukaemia

18 March 2024

36

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

Overexpression of lung-resistance protein and increased P-glycoprotein function in acute myeloid leukaemia cells predict a poor response to chemotherapy and reduced patient survival.

18 March 2024

37

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance.

18 March 2024

38

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

P-glycoprotein: the intermediate end point of drug response to induction chemotherapy in locally advanced breast cancer.

18 March 2024

39

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

Sequential assessment of multidrug resistance phenotype and measurement of S-phase fraction as predictive markers of breast cancer response to neoadjuvant chemotherapy.

18 March 2024

40

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

Diagnosis and reversal of multidrug resistance in paediatric cancers

18 March 2024

43

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

High level expression of the multidrug resistance (MDR1) gene in the normal bladder urothelium: a potential involvement in protection against carcinogens?

18 March 2024

44

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

Alterations in expression of the multidrug resistance-associated protein (MRP) gene in high-grade transitional cell carcinoma of the bladder

18 March 2024

45

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

Increased expression of multidrug resistance-associated proteins in bladder cancer during clinical course and drug resistance to doxorubicin

18 March 2024

46

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

P-glycoprotein expression in bladder cancer

18 March 2024

47

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

Clinical Significance of Multi-Drug Resistance Associated Protein and P-Glycoprotein in Patients with Bladder Cancer

18 March 2024

48

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

Frequent expression of the multi-drug resistance-associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP-21 monoclonal antibody in paraffin-embedded material

18 March 2024

50

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

An altered pattern of cross-resistance in multidrug-resistant human cells results from spontaneous mutations in the mdr1 (P-glycoprotein) gene

18 March 2024

51

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs

18 March 2024

52

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

Modulation of multidrug-resistant multiple myeloma by cyclosporin. The Leukaemia Group of the EORTC and the HOVON

18 March 2024

54

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

Clinical modulation of multidrug resistance in multiple myeloma: effect of cyclosporine on resistant tumor cells

18 March 2024

55

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC-HOVON randomized phase III study (06914).

18 March 2024

56

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A Southwest Oncology Group study

18 March 2024

57

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

Cyclosporins as drug resistance modifiers

18 March 2024

58

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel

18 March 2024

60

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

Safety and efficacy of the multidrug-resistance inhibitor biricodar (VX-710) with concurrent doxorubicin in patients with anthracycline-resistant advanced soft tissue sarcoma

18 March 2024

61

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

Phase I study of paclitaxel in combination with a multidrug resistance modulator, PSC 833 (Valspodar), in refractory malignancies.

18 March 2024

63

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

Phase I and pharmacokinetic study of the novel MDR1 and MRP1 inhibitor biricodar administered alone and in combination with doxorubicin

18 March 2024

66

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer.

18 March 2024

68

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study

18 March 2024

69

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

Verapamil increases the survival of patients with anthracycline-resistant metastatic breast carcinoma

18 March 2024

72

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

Oral verapamil with chemotherapy for advanced non-small cell lung cancer: a randomised study

18 March 2024

73

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study.

18 March 2024

74

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP.

18 March 2024

75

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy

18 March 2024

76

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833.

18 March 2024

77

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

In vitro prevention of the emergence of multidrug resistance in a pediatric rhabdomyosarcoma cell line

18 March 2024

78

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia

18 March 2024

79

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

Kinetic concepts in the systemic drug therapy of breast cancer

18 March 2024

80

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

Coadministration of oral cyclosporin A enables oral therapy with paclitaxel

18 March 2024

81

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

Phase II and pharmacologic study of weekly oral paclitaxel plus cyclosporine in patients with advanced non-small-cell lung cancer

18 March 2024

82

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

Weekly oral paclitaxel as first-line treatment in patients with advanced gastric cancer

18 March 2024

83

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

Inhibition of intestinal P-glycoprotein and effects on etoposide absorption.

18 March 2024

84

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

Polymorphisms in the ABC drug transporter gene MDR1.

18 March 2024

85

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

Region-dependent modulation of intestinal permeability by drug efflux transporters: in vitro studies in mdr1a(-/-) mouse intestine

18 March 2024

86

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918.

18 March 2024

88

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

A phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide, and the MDR modulator PSC 833: a southwest oncology group study 9617.

18 March 2024

89

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

MRP and MDR1 gene expression in primary breast carcinomas

18 March 2024

94

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

Multidrug resistance related genes and p53 expression in human non small cell lung cancer

18 March 2024

96

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas

18 March 2024

97

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

Immunohistochemical evidence that P-glycoprotein in non-small cell lung cancers is associated with shorter survival

18 March 2024

98

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

Expression of multidrug resistance-associated protein gene in Ewing's sarcoma and malignant peripheral neuroectodermal tumor of bone

18 March 2024

99

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

Effect of P-glycoprotein expression on outcome in the Ewing family of tumors.

18 March 2024

100

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

Expression of multidrug resistance protein gene in patients with glioma after chemotherapy.

18 March 2024

101

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

Drug resistance-associated factors in primary and secondary glioblastomas and their precursor tumors.

18 March 2024

102

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

Expression of Multidrug-Resistance (MDR1) Gene in Normal Epithelia and in Invasive Carcinomas of the Uterine Cervix

18 March 2024

103

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

Immunohistochemical detection of the multi-drug-resistance marker P-glycoprotein in uterine cervical carcinomas and normal cervical tissue

18 March 2024

104

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

Expression and activity of breast cancer resistance protein (BCRP) in de novo and relapsed acute myeloid leukemia.

18 March 2024

106

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

Breast cancer resistance protein expression and resistance to daunorubicin in blast cells from patients with acute myeloid leukaemia

18 March 2024

107

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML)

18 March 2024

108

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia

18 March 2024

109

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

Expression of multidrug resistance-related transporters in human breast carcinoma

18 March 2024

110

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

Multidrug resistance related molecules in human and murine lung

18 March 2024

112

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial

18 March 2024

113

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

A randomised clinical study of verapamil in addition to combination chemotherapy in small cell lung cancer. West of Scotland Lung Cancer Research Group, and the Aberdeen Oncology Group

18 March 2024

114

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-411

18 March 2024

Identifiers

1 reference

1 August 2017

1 reference